Natus Medical (NASDAQ:NTUS) Issues Q4 2019 Pre-Market Earnings Guidance

Natus Medical (NASDAQ:NTUS) issued an update on its fourth quarter 2019
Pre-Market earnings guidance on Monday morning. The company provided EPS guidance of 0.44-0.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.47. The company issued revenue guidance of $128-132 million, compared to the consensus revenue estimate of $130 million.Natus Medical also updated its Q4 guidance to $0.44-0.47 EPS.

NASDAQ:NTUS opened at $33.68 on Tuesday. The stock has a market cap of $1.14 billion, a P/E ratio of 27.32 and a beta of 0.69. Natus Medical has a twelve month low of $22.25 and a twelve month high of $34.89. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 1.87. The stock’s 50 day moving average is $32.31.

Natus Medical (NASDAQ:NTUS) last released its earnings results on Thursday, October 24th. The company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.02). The company had revenue of $123.46 million for the quarter, compared to analysts’ expectations of $124.75 million. Natus Medical had a positive return on equity of 10.43% and a negative net margin of 4.71%. The firm’s revenue for the quarter was down 5.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 EPS. As a group, research analysts anticipate that Natus Medical will post 1.25 earnings per share for the current fiscal year.

NTUS has been the topic of several research analyst reports. TheStreet raised shares of Natus Medical from a d+ rating to a c- rating in a research report on Monday, September 30th. Zacks Investment Research downgraded shares of Natus Medical from a hold rating to a sell rating in a research report on Wednesday, January 8th.

In other news, VP Dong Chune Christopher Chung sold 14,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $33.67, for a total value of $471,380.00. Also, CEO Jonathan Kennedy sold 8,676 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $32.65, for a total transaction of $283,271.40. Insiders sold a total of 29,360 shares of company stock worth $965,465 over the last ninety days. Insiders own 1.65% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: Why do commodities matter?

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.